UCB's Global Corporate Website
Welcome to UCB in the United States

Categories

Archives

Jan

13

Patient-first: UCB is there to listen to patients, to not only learn more about them but also from them

Read More Share:linkedin| twitter| email

Jan

06

UCB announces rozanolixizumab BLA for the treatment of generalized myasthenia gravis filed with U.S. FDA and designated for Priority Review

Read More Share:linkedin| twitter| email

Nov

14

UCB announces U.S. FDA acceptance of new drug application and EMA MAA validation for zilucoplan for the treatment of generalized myasthenia gravis in adult patients

Read More Share:linkedin| twitter| email

Sep

22

UCB presents latest data from generalized myasthenia gravis portfolio at AANEM meeting

Read More Share:linkedin| twitter| email

Jun

01

Life with MG & What I Wish For Everyone Who is Diagnosed

Read More Share:linkedin| twitter| email

May

27

My Commitment to the Newly Diagnosed and All People Living with Myasthenia Gravis

Read More Share:linkedin| twitter| email

May

10

UCB presents efficacy and safety results for zilucoplan and rozanolixizumab in generalized myasthenia gravis

Read More Share:linkedin| twitter| email

Feb

25

Recognizing Rare Disease Day Every Day – The Importance of Addressing Unmet Patient Needs

At UCB, we work 365-days-a-year to find new ways to deliver solutions, peace of mind, and opportunities to people living with severe diseases because everyone deserves to live the best life they can.

Read More Share:linkedin| twitter| email

Feb

04

UCB announces positive data in myasthenia gravis with zilucoplan phase 3 study results

Read More Share:linkedin| twitter| email

Dec

10

UCB announces positive Phase 3 results for rozanolixizumab in generalized myasthenia gravis

Read More Share:linkedin| twitter| email

© 2009 - 2020 UCB, Inc., Atlanta. All rights reserved.
USPR-CORP-0115-00003(2)